In chronic myeloid leukemia (CML) ex vivo generated DC are characterized by constitutive expression of bcr/abl and possibly other yet undefined leukemia-associated antigens, since these DC share a common progeny with leukemic cells. Induction of anti-leukemic T cell responses has been described in vitro. For a phase I vaccination study, autologous bcr/abl؉ DC are generated under GMP conditions mainly from monocyte precursors in chronic phase CML patients. Lin Induction of T cell immunity against leukemic cells by dendritic cells (DC) has been demonstrated in vitro both in chronic myeloid leukemia (CML) and in acute myeloid leukemia (AML).
Induction of T cell immunity against leukemic cells by dendritic cells (DC) has been demonstrated in vitro both in chronic myeloid leukemia (CML) and in acute myeloid leukemia (AML). [1] [2] [3] Chimeric fusion proteins resulting from chromosomal translocations can be considered as ideal target molecules for cytotoxic T cell responses, since these molecules are restricted to the malignant cell clone. In CML Ͼ90% of the patients express the 210 kDa chimeric fusion proteins bcr2/abl2 or bcr3/abl2. Both fusion proteins possess abnormal tyrosine kinase activity and play a key role in the pathogenesis of the disease. Within the fusion region of the bcr3/abl2 protein, different peptides have been identified which bind to HLA-A2, -A3, -A11 and -B8. 3, 4 Induction of cytotoxic T cell responses against distinct HLA-peptide complexes and against HLA-matched, as well 3,5-7 Furthermore, several HLA class II binding peptides have been isolated from the bcr/abl fusion region. Since DC can be generated in vitro from bcr/abl-positive precursors -CD34 ϩ cells and monocytes -the resulting DC population is largely bcr/abl-positive. In chronic phase CML, cytotoxic anti-leukemic T cell responses can be elicited by these unmodified DC, 1, 8 possibly by constitutive presentation of bcr/ablϪ or other yet unknown peptides.
In our GMP laboratory, autologous unmodified DC are generated as vaccine in patients with chronic phase bcr/ablpositive CML.
Materials and methods

Generation of DC for clinical application from monocytes according to GMP criteria
DC were generated from patients with chronic phase bcr/ablϩ CML according to our study protocol which had been approved by the local ethics committee. Peripheral blood mononuclear cells (PBMC) were collected by standard leukapheresis using an AS 104 cell separator (Fresenius, Bad Homburg, Germany). PBMC were further enriched by density gradient centrifugation on Lymphoprep (Life Technologies, Karlsruhe, Germany) and then stored on liquid nitrogen using RPMI 1640 (BioWhittaker, Verviers, Belgium) with 42.5% Human Serum Albumin (HSA, Octapharm) and 10% DMSO (Sigma). Thawing of PBMC was performed by addition of HBSS w/o Caϩϩ/Mgϩϩ (BioWhittaker) containing 5% HSA. PBMC were washed twice and then exposed to plastic adherence for monocyte enrichment. Briefly, PBMC were seeded at a density of 1.4 ϫ 10 6 /cm 2 in 185 cm 2 culture flasks (Nunc, Wiesbaden, Germany) and allowed to adhere for 2 h at 37°C in RPMI 1640 containing 5% HSA and 1% sodium pyruvate. Nonadherent cells were removed by washing four times. Adherent cells were cultured in RPMI 1640 supplemented with 100 ng GM-CSF (Leukomax, Novartis, Nürnberg, Germany), 1000 U/ml clinical grade interleukin-4 (kindly provided by Shering-Plough Research Institute, Kenilworth, NJ, USA), 10% fetal calf serum (FCS, Summit, Fort Collins, CO, USA) and 1% sodium pyruvate for 5 days. On day 5, 50 ng clinical grade TNF-␣ (Bender, Vienna, Austria) was added to the culture medium for another 3-4 days. On day 8-9, DC were harvested and washed three times. Viability was determined by trypan blue staining. Furthermore, gram staining and microbiological sterile controls were performed.
Generation of DC from CD34
ϩ cells CD34 ϩ cells were enriched from leukapheresis products using an Isolex 300 device (Baxter, Unterschleissheim, Germany) according to the manufacturer's instructions. 9 
CD34
ϩ cells were seeded at 5 ϫ 10 5 cells/ml in RPMI 1640 supplemented with 4 mm l-glutamine (Gibco, Karlsruhe, Germany), 5 ϫ 10 −5 m 2-mercaptoethanol (Roth, Karlsruhe, Germany), 100 U/ml penicillin/streptomycin (Gibco), 10% heat-inactivated FCS (Gibco), 100 ng GM-CSF (Leukomax, Novartis), 1000 U/ml interleukin-4 (SheringPlough) and 10 ng/ml TNF-␣ (Boehringer, Mannheim, Germany) for 12 days. Two of three of the media were replaced every 3-4 days.
FACS analysis
Phycoerythrin (PE)-conjugated mouse monoclonal antibodies against the following antigens were used: CD1a, CD3, CD4, CD14, CD19, CD80, CD86, HLA-DR, MHC class I, PE-conjugated isotype control antibody (BectonDickinson, Mountain View, CA, USA) and CD83 (Immunotech, Hamburg,Germany).
Retroviral transduction of dendritic cells
IL-7 gene transduction was performed with the LXSN-hIL-7 vector, using helper virus free retroviral supernatant with a virus titer of 2 ϫ 10 6 cfu/ml on NIH 3T3 cells as previously described. 10 Briefly, 1.0 ml viral supernatant was added to 1 ϫ 10 6 target cells in 1.0 ml medium. Twelve hours later, two of three of the media were exchanged. This procedure was performed on culture days 3, 5, 8 and 10. On day 12, cells were extensively washed and medium was changed completely. IL-7 production was then measured in the cell culture supernatants by ELISA (R&D Systems, Minneapolis, MN, USA) 24 h later. Mock infections were carried out in a similar way.
Mixed lymphocyte reaction (MLR)
Autologous MLR was performed as previously described. 10 Briefly, 625 to 10 000 irradiated (30 Gy) DC were used as stimulator cells together with 10 5 autologous T cells as responder cells in RPMI 1640 containing 10% FCS as a source of foreign antigen in a 5-day standard 3 H-thymidine incorporation assay.
Results
DC for clinical application in CML patients
GMP production of DC has been performed in three patients with bcr/abl-positive chronic phase CML for 12 vaccinations according to our study protocol. Due to concomitant therapy with hyroxyurea Ϯ ␣-interferon, the numBone Marrow Transplantation ber of CD34 ϩ cells in peripheral blood was not sufficient for enrichment of stem cells. DC generation was performed from monocytes in these patients. In three patients, a mean WBC count of 2.77 ϫ 10 10 could be collected in two 4 h leukaphereses. After Ficoll gradient centrifugation, a mean of 1.39 ϫ 10 10 PBMC could be frozen for later DC generation. After 5 days of culture, monocyte precursor cells had acquired a morphology which was characteristic of DC. Viability was always Ͼ70%, T cells were less than 5%. FACS analysis after 5 days showed an immature phenotype which was CD1a
Ϫ . After a further 3-4 days of culture in the presence of TNF-␣, FACS analysis revealed upregulation of CD80, CD86, CD83 and DR (Table 1 ). In the DC preparations analyzed so far, bcr/abl expression was demonstrated by FISH in Ͼ70% of the cells (in collaboration with H and C Döhner, Dept Hematology/Oncology, University of Ulm, Ulm, data not shown). In 12 DC preparations for clinical application, the mean yield of DC per 10 8 seeded PBMC was 2.06% with a range of 0.27-6.0% (Table 2) .
Retroviral interleukin-7 gene transfer into CD34
ϩ -derived DC in CML Using repetitive infection cycles with the retroviral vector LXSN-hIL-7, 10 a mean IL-7 production of 3040 ϩ 1859 pg/10 6 cells/24 h was achieved in six experiments with CD34-derived DC from CML patients. In order to compare the T cell stimulatory ability of IL-7 secreting DC with mock transfected and unmodified DC, autologous MLR was performed with autologous T cells as responder cells. IL-7 transduction of DC lead to an increase in T cell proliferation by a factor 2-3 ( Figure 1 ).
Discussion
In chronic myeloid leukemia, bcr/ablϩ autologous DC can be generated from peripheral blood monocytes on a clinical scale according to GMP criteria. Functional integrity of DC in CML has previously been demonstrated by our group and others. 1, 8 Monocyte enrichment by plastic adherence was easily applicable under GMP conditions, lead to a reproducibly good T cell depletion and had a good cost efficiency as compared with negative selection by immunological methods. The yield of DC per seeded PBMC was in the range of 1-6%. Cell losses were caused by thawing, adherence, washing procedures and a naturally occurring decrease in the cell number, especially during the last days of cell culture. DC yield was in line with the data of a different group which generated DC from frozen PBMC.
11
Final maturation of DC with a significant upregulation of CD80, CD86, CD83 and DR could be achieved by TNF-␣ in 3-4 days. Nevertheless, the question whether clinical application of mature DC has any advantage over immature DC remains controversial and has to be addressed in clinical trials. Induction of anti-leukemic T cell immunity is under evaluation in our vaccination study by Elispot and T cell proliferation assays. In analogy with previous results using DC from healthy donors, 10 we also found increased Data from 12 DC preparations for four vaccinations/patient with increasing cell numbers in each patient.
Table 2
Surface marker expression of monocyte-derived DC after cultivation in the presence of GM-CSF/IL-4 for 5 days and in GM-CSF/IL-4/TNF-␣ for a further 3-4 days T cell stimulatory ability of IL-7 transduced, CD34-derived DC from CML patients. For clinical applications, IL-7-secreting DC might provide an additional signal to induce anti-leukemic T cell immunity, possibly helping to break pre-existing tolerance. In vitro, IL-7 has been reported to restore T cell immunity against autoantigens. 12 The question whether unmodified bcr/abl+ DC are sufficient to induce T cell immunity or whether additional peptide/ protein-pulsing Ϯ gene modification of DC is necessary will have to be addressed in further clinical trials. Postremission immunotherapy after autologous stem cell transplantation might be of particular interest for DC-based vaccination strategies.
Surface marker 5 days GM-CSF/IL-4 Additional 3-4 days GM-CSF/ ILl-4/TNF-␣
CD3 Neg Neg CD19 Neg Neg CD14 Neg/(ϩ) Neg CD4 ϩϩ ϩϩ CD1a ϩϩ ϩ CD80 ϩ ϩ ϩ CD86 ϩ ϩ ϩ CD83 Neg ϩ HLA-DR ϩϩ ϩϩϩ
